NZ601194A - Compounds as bradykinin b1 antagonists - Google Patents

Compounds as bradykinin b1 antagonists

Info

Publication number
NZ601194A
NZ601194A NZ601194A NZ60119411A NZ601194A NZ 601194 A NZ601194 A NZ 601194A NZ 601194 A NZ601194 A NZ 601194A NZ 60119411 A NZ60119411 A NZ 60119411A NZ 601194 A NZ601194 A NZ 601194A
Authority
NZ
New Zealand
Prior art keywords
pain
phenylamino
pyridazine
dihydro
oxo
Prior art date
Application number
NZ601194A
Inventor
Rainer Walter
Norbert Hauel
Dieter Wiedenmayer
Henning Priepke
Ingo Konetzki
Angelo Ceci
Juergen Mack
Henri Doods
Annette Schuler-Metz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/052232 external-priority patent/WO2010097372A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NZ601194A publication Critical patent/NZ601194A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed herein are compound of general formula I, wherein the variables are defined in the specification, and the use thereof in the treatment of acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain, headache diseases and osteoarthritis. In some embodiments the compound includes (S)-6-oxo-1,6-dihydro-pyridazine-4-carboxylic acid-{ 3-[4-(4-chloro-2-trifluoromethyl-phenylamino)-2-fluoro-benzylcarbamoyl]-tetrahydrofuran-3-yl} -amide, and 6-oxo-1,6-dihydro-pyridazine-4-carboxylic acid-(1-{ [5-(4-fluoro-2-trifluoromethyl-phenylamino)-pyridin-2-ylmethyl]-carbamoyl} -cyclopropyl)-amide.
NZ601194A 2010-02-23 2011-02-21 Compounds as bradykinin b1 antagonists NZ601194A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/052232 WO2010097372A1 (en) 2009-02-26 2010-02-23 Compounds as bradykinin b1 antagonists
PCT/EP2011/052512 WO2011104203A1 (en) 2010-02-23 2011-02-21 Compounds as bradykinin b1 antagonists

Publications (1)

Publication Number Publication Date
NZ601194A true NZ601194A (en) 2014-10-31

Family

ID=43981434

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601194A NZ601194A (en) 2010-02-23 2011-02-21 Compounds as bradykinin b1 antagonists

Country Status (23)

Country Link
EP (1) EP2539323B3 (en)
JP (1) JP5603955B2 (en)
KR (1) KR101843341B1 (en)
CN (2) CN102781916B (en)
AP (1) AP3218A (en)
AR (1) AR080249A1 (en)
AU (1) AU2011219885C1 (en)
CA (1) CA2790952C (en)
CY (1) CY1116182T1 (en)
DK (1) DK2539323T6 (en)
ES (1) ES2531663T7 (en)
HK (1) HK1175171A1 (en)
IL (1) IL220680A (en)
MA (1) MA34008B1 (en)
MX (1) MX2012009224A (en)
NZ (1) NZ601194A (en)
PE (1) PE20121805A1 (en)
PL (1) PL2539323T6 (en)
PT (1) PT2539323E (en)
SG (1) SG183336A1 (en)
SI (1) SI2539323T1 (en)
TW (1) TWI499589B (en)
WO (1) WO2011104203A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007034620A1 (en) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg New B1 antagonists
ATE550321T1 (en) 2007-08-29 2012-04-15 Boehringer Ingelheim Int NEW BRADYKININ B1 ANTAGONISTS
AP3218A (en) 2010-02-23 2015-04-30 Boehringer Ingelheim Int Compounds as bradykinin B1 antagonists
US8901127B2 (en) 2010-08-20 2014-12-02 Boehringer Ingelheim International Gmbh Pyridazin derivatives as antagonists of the bradykinin B1 receptor
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
JP7376582B2 (en) * 2018-10-22 2023-11-08 イーオーイー オレオ ゲーエムベーハー Additive for powder materials for compression into compacts
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038377A1 (en) * 2002-02-08 2005-01-12 Merck & Co Inc DERIVATIVES OF N-BIFENIL-AMINOCICLOALCANCARBOXAMIDA (WITH REPLACEMENT WITH METHYL)
IL166426A0 (en) 2002-08-29 2006-01-15 Merck & Co Inc N-biarylmethyl aminocycloalkanecarboxamide derivatives
CA2534188A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
US20070189865A1 (en) * 2004-03-02 2007-08-16 Bock Mark G Amino cyclopropane carboxamide derivatives as bradykinin antagonists
MX2007013766A (en) 2005-05-11 2008-01-28 Nycomed Gmbh Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative.
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
UA105923C2 (en) 2009-02-26 2014-07-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Compounds as bradykinin b1 antagonists
AP3218A (en) 2010-02-23 2015-04-30 Boehringer Ingelheim Int Compounds as bradykinin B1 antagonists

Also Published As

Publication number Publication date
CA2790952A1 (en) 2011-09-01
TWI499589B (en) 2015-09-11
PT2539323E (en) 2015-02-16
PL2539323T6 (en) 2018-05-30
MX2012009224A (en) 2012-08-23
SI2539323T1 (en) 2015-03-31
AP2012006330A0 (en) 2012-06-30
KR101843341B1 (en) 2018-03-30
PL2539323T3 (en) 2015-05-29
DK2539323T3 (en) 2015-02-23
ES2531663T7 (en) 2018-02-13
JP5603955B2 (en) 2014-10-08
EP2539323B3 (en) 2017-10-04
AU2011219885C1 (en) 2017-06-29
CN102781916B (en) 2014-06-25
SG183336A1 (en) 2012-09-27
EP2539323B1 (en) 2014-12-03
CN102781916A (en) 2012-11-14
ES2531663T3 (en) 2015-03-18
CY1116182T1 (en) 2017-02-08
AU2011219885A1 (en) 2012-08-02
KR20130025864A (en) 2013-03-12
CN103980258A (en) 2014-08-13
PE20121805A1 (en) 2013-01-23
HK1175171A1 (en) 2013-06-28
IL220680A0 (en) 2012-08-30
AP3218A (en) 2015-04-30
MA34008B1 (en) 2013-02-01
AR080249A1 (en) 2012-03-21
AU2011219885B2 (en) 2015-10-15
EP2539323A1 (en) 2013-01-02
WO2011104203A1 (en) 2011-09-01
CN103980258B (en) 2016-09-07
TW201141848A (en) 2011-12-01
IL220680A (en) 2015-08-31
JP2013519710A (en) 2013-05-30
CA2790952C (en) 2017-07-04
DK2539323T6 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
NZ601194A (en) Compounds as bradykinin b1 antagonists
HK1216100A1 (en) 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro- 2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases raf 1-(3-(67--4- ))-3-(5-(111--2--2-)-3-)
NZ596826A (en) Polycyclic antagonists of lysophosphatidic acid receptors
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
NZ607795A (en) Estrogen receptor modulators and uses thereof
NZ596882A (en) Disubstituted phthalazine hedgehog pathway antagonists
HK1226069A1 (en) 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl (2,3,4,5,6-penta-hydroxyhexyl)amino)ethoxy)phenyl)butyl) carbamimidoyl) pyrazine-2-carboxamide
NZ593004A (en) Azaazulene compounds
NZ611314A (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
NZ722400A (en) Idh1 mutant inhibitors, pharmaceutical compositions comprising them, and their use in the treatment of cancer
HRP20182059T1 (en) Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{ [4-(1-methylethyl)-1-piperazinyl]methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
MX353257B (en) Heterocyclic compounds useful as pdk1 inhibitors.
NZ599290A (en) Antimicrobial compounds and methods of making and using the same
MY159575A (en) Dihydroorotate dehydrogenase inhibitors
CO6801777A2 (en) Modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoro -methyl) -phenyl] -benzamide solubilized using organic acids
MX2013004004A (en) Pyrrolidinones as metap2 inhibitors.
MY160880A (en) Crystalline form of an inhibitor of mdm2/4 and p53 interaction
MX2010009416A (en) Heterocyclic compounds as inhibitors of cxcr2.
HK1124048A1 (en) 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
NZ601121A (en) 5-alkynyl-pyrimidines
CL2013000884A1 (en) Compound (r) - (e) -2- (4- (2- (5- (1- (3,5-dichloropyridin-4-yl) ethoxy) -1h-indazol-3-yl) vinyl) -1h -pyrazol-1-yl) crystalline ethanol, fibroblast growth factor modulator (fgf); pharmaceutical composition, useful in the treatment of cancer.
NZ611528A (en) Neprilysin inhibitors
TW201129554A (en) 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
CY1111701T1 (en) 5- [3- (3-Hydroxyphenoxy) azetidin-1-yl] -5-methyl-2,2-diphenylhexylamide hydrochloride salt
WO2013150545A3 (en) Process for preparation of benzimidazole derivatives and salts thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2016 BY SPRUSON + FERGUSON

Effective date: 20150519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2017 BY DENNEMEYER + CO

Effective date: 20160122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2018 BY DENNEMEYER + CO.

Effective date: 20170120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2019 BY DENNEMEYER + CO

Effective date: 20180123

LAPS Patent lapsed